Ravindra Ashokbhai Joshi

Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. Statutory auditors issued a disclaimer of opinion on both sets of results due to insufficient a

Auditors issued disclaimer opinion on Vaxfab's FY26 results due to inadequate prior period records and documentation. Standalone FY26 profit was ₹363.80 lakhs, while consolidated results showed a loss